Novel approaches to the treatment of hyperhomocysteinaemia

Expert Opinion on Therapeutic Patents

Volumn 13, Issue 7, 2003, Pages 1023-1035

  Obregon, Demian F ^a   Murthy, Subramanyam N ^a   McNamara, Dennis B ^a   Fonseca, Vivian A ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Cardiovascular disease (CVD); Folate; Folic acid; Homocysteinaemia; Homocysteine; Hyperhomocysteinaemia; Methionine

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETAINE; COBALAMIN; CYANOCOBALAMIN; ETHINYLESTRADIOL; FENOFIBRATE; FOLIC ACID; FOLINATE CALCIUM; FOLINIC ACID; HOMOCYSTEINE; LEVONORGESTREL; METFORMIN; METHIONINE; PROGESTERONE; PYRIDOXINE; RALOXIFENE; RAZOXANE; SULFUR DERIVATIVE; TETRAHYDROFOLIC ACID DERIVATIVE;

AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SYNTHESIS; HEMODIALYSIS PATIENT; HORMONE SUBSTITUTION; HUMAN; HYPERHOMOCYSTEINEMIA; KIDNEY DISEASE; LOW DRUG DOSE; PATENT; PROTEIN ANALYSIS; PROTEIN STRUCTURE; REVIEW; TREATMENT PLANNING; VITAMIN SUPPLEMENTATION;

EID: 0038235845     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.13.7.1023     Document Type: Review

References (86)

1. CARSON NAJ, DENT CE, FIELD CMB, GAULL GE: Homocystinuria: clinical and pathological review of ten cases. J. Ped. (1965) 66(3):565-583.
2. MCCULLY KS: Vascular pathology of homocysteinemia. Implications for the pathogenesis of arteriosclerosis. Am. J. Pathology (Phila.) (1969) 56:111-128.
3. BOERS GH, SMALS AG, TRIJBELS FJ et al.: Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N. Engl. J. Med. (1985) 313(12)709-715.
4. KLUIJTMANS LA, VAN DEN HEUVEL LP, BOERS GH et al.: Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am. J. Hum. Genet. (1996) 58(1):35-41.
5. WALD NJ, WATT HC, LAW MR, WEIR DG, MCPARTLIN J, SCOTT JM: Homocysteine and ischemic heart disease. Arch. Intern. Med. (1998) 158:862-867.
6. 6, pyridoxal phosphate, and folate. Am. J. Cardiol. (1995) 75:1107-1111.
7. SELHUB J, JACQUES PF, BOSTOM AG et al.: Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N. Engl. J. Med. (1995) 332:286-291.
8. STAMPFER MJ, MALINOW MR, WILLETT WC et al.: A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA (1992) 268(7):877-881.
9. BOUSHEY CJ, BERESFORD SAA, OMENN GS, MOTULSKY AG: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA (1995) 274:1049-1057.
10. CLARKE R, DALY L, ROBINSON K et al.: Hyperhomocysteinemia: an independent risk factor for vascular disease. N. Engl. J. Med. (1991) 324:1149-1155.
11. DEN HEIJER M, KOSTER T, BLOM HJ et al.: Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N. Engl. J. Med. (1996) 334:759-762.
12. MANDEL H, BRENNER B, BERANT M et al.: Coexistence of hereditary homocystinuria and Factor V leiden - effect on thrombosis. N. Engl. J. Med. (1996) 334:763-768.
13. GRAHAM IM, DALY LE, REFSUM HM et al.: Plasm homocysteine as a risk factor for vascular disease. JAMA (1997) 277:1775-1781.
14. FOLSOM AR, NIETO J, MCGOVERN PG et al.: Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins. The atherosclerosis risk in communities (ARIC) study. Circulation (1998) 98:204-210.
15. EVANS, RW, SHATEN BJ, HEMPEL JD, CUTLER JA, KULLER LH: Homocysteine and risk of cardiovascular disease in the multiple risk factor intervention trial. Arterioscler. Thromb. Vasc. Biol. (1997) 17:1947-1953.
16. SCHORAH CJ, DEVITT H, LUCOCK M, DOWELL AC: The responsiveness of plasma homocysteine to small increases in dietary folic acid: a primary care study. Eur. J. Clin. Nutr. (1998) 52:407-411.
17. MALINOW MR, DUELL PB, HESS DL et al.: Reduction of plasma homocysteine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. N. Engl. J. Med. (1998) 338:1009-1015.
18. VENN BJ, MANN JI, WILLIAMS SM et al.: Dietary counseling to increase natural folate intake: a randomized, placebo-controlled trial in free-living subjects to assess effects on serum folate and plasma total homocysteine. Am. J. Clin. Nutr. (2002) 76:758-765.
19. RIDDELL LJ, CHISHOLM A, WILLIAMS S, MANN JI: Dietary strategies for lowering homocysteine concentrations. Am. J. Clin. Nutr. (2000) 71:1448-1454.
20. TICE JA, ROSS E, COXSON PG et al.: Cost-effectiveness of vitamin therapy to lower plasma homocysteine levels for the prevention of coronary heart disease: effect of grain fortification and beyond. JAMA (2001) 286(8):936-943.
21. HOMOCYSTEINE LOWERING TRIALISTS' COLLABORATION: Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomized trials. BMJ (1998) 316:894-898.
22. MALINOW MR, NIETO FJ, KRUGER WD et al.: The effects of folic acid supplements on plasma total homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase genotypes. Arterioscler. Thromb. Vasc. Biol. (1997) 17:1157-1162.
23. WOO KS, CHOOK P, CHAN LLT et al.: Long-term improvement in homocysteine levels and arterial endothetial function after 1-year folic acid supplementation. Am. J. Med. (2002) 112(7):535-539.
24. VAN DER GRIEND R, BIESMA DH, HAAS FJLM et al.: The effect of different treatment regimens in reducing fasting and postmethionine-load homocysteine concentrations. J. Int. Med. (2000) 248:223-229.
25. FOHR IP, PRINZ-LANGENOHL R, BRÖNSTROP A et al.: 5,10-Methylenetetrahydrofolate reductase genotype determines the plasma-homocysteine-lowering effect of supplementation with 5-methylenetetrahyrofolate or folic acid in healthy young women. Am. J. Clin. Nutr. (2002) 75:275-282.
26. GUTTORMSEN AB, UELAND PM, NESTHUS I et al.: Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (40 μmol/l). The Hordaland homocysteine study. J. Clin. Invest. (1996) 98:2174-2183.
27. FRANKEN DG, BOERS GH, BLOM HJ, TRIJBELS FJ, KLOPPENBORG PW: Treatment of mild hyperhomocysteinemia in vascular disease patients. Arterioscler. Thromb. (1994) 14:465-470.
28. 6 status on homocysteine metabolism. J. Clin. Invest. (1996) 98:177-184.
29. UBBINK JB, VERMAAK WJH, VAN DER MERWE A, BECKER PJ, DELPORT R, POTGIETER HC: Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J. Nutr. (1994) 124:1927-1933.
30. BRATTSTRÖM L, ISRAELSSON B, NORRVING B et al.: Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease. Atherosclerosis (1990) 81:51-60.
31. 6 plus folic acid therapy in young patients with arteriosclerosis and hyperhomocysteinemia. J. Vasc. Surg. (1994) 20:933-940.
32. DUDMAN NP, WILCKEN DE, WANG J, LYNCH JF, MACEY D, LUNDBERG P: Disordered methionine/homocysteine metabolism in premature vascular disease. Its occurrence, cofactor therapy, and enzymology. Arterioscler. Thromb. (1993) 13:1253-1260.
33. SIMOLIN LA, BENEVENGA NJ, BERLOW S: The use of betaine for the treatment of homocystinuria. J. Pediatr. (1981) 99:467-472.
34. WILCKEN DE, WILCKEN B, DUDMAN P, TYRRELL PA: Homocystinuria - the effect of betaine in the treatment of patients not responsive to pyridoxine. N. Engl. J. Med. (1983) 309:448-453.
35. BALIGA BS, REYNOLDS T, FINK LM, FONSECA VA: Hyperhomocysteinemia in Type 2 diabetes mellitus: cardiovascular risk factors and effect of treatment with folic acid and pyridoxine. Endocr. Pract. (2000) 6(6):435-441.
36. BOSTOM AG, COLLETON BF: Hyperhomocysteinemia in chronic renal disease. J. Am. Soc. Nephrol. (1999) 10:891-900.
37. VAN GULDENER C, JANSSEN MJFM, DE MEER K, DONKER AJM, STEHOUWER CDA: Effect of folic acid and betaine on fasting and postmethionine-loading plasma homocysteine and methionine levels in chronic haemodialysis patients. J. Int. Med. (1999) 245:175-183.
38. VAN GULDENER C, JANSSEN MJ, LAMBERT J et al.: No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinaemia in haemodialysis patients. Nephr. Dialysis Transpl. (1998) 13(1):106-112.
39. BOSTOM AG, SHEMIN D, LAPANE KL et al.: High dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int. (1996) 49(1):147-152.
40. 12. Nephrol. Dial. Transplant. (2002) 17:455-461.
41. TREMBLAY R, BONNARDEAUX A, GEADAH D et al.: Hyperhomocysteinemia in hemodialysis patients: effects of 12-month supplementation with hydrosoluble vitamins. Kidney Int. (2000) 58:851-858.
42. SUNDER-PLASSMANN G, FÖDINGER M, BUCHMAYER H et al.: Effect of high-dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: results from the Vienna Multicenter Study. J. Am. Soc. Nephrol. (2000) 11:1106-1116.
43. 12 and high-dose folic acid in hemodialysis patients with hyperhomocyst(e)inemia. Kidney Int. (2001) 59:1103-1109.
44. TOUAM M, ZINGRAFF J, JUNGERS P, CHADEFAUX-VEKEMANS B, DRÜEKE T, MASSY ZA: Effective correction of hyperhomocysteinemia in hemodialysis patients by intravenous folinic acid and pyridoxine therapy. Kidney Int. (1999) 56:2292-2296.
45. BOSTOM AG, SHEMIN D, GOHH RY et al.: Treatment of hyperhomocysteinemia in hemodialysis patients and renal transplant recipients. Kidney Int. (2001) 59(S78):S246-S252.
46. BOSTOM AG, SHEMIN D, BAGLEY P et al.: Controlled comparison of L-5-methyltetrahydrofolate versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients. Circulation (2000) 101:2829-2832.
47. BOSTOM AG, SHEMIN D, GOHH RY et al.: Treatment of mild hyperhomocysteinemia in renal transplant recipients versus hemodialysis patients. Transplantation (2000) 69:2128-2131.
48. BEAULIEU AJ, GOHH RY, HAN H, HAKAS D et al.: Enhanced reduction of fasting total homocysteine levels with supraphysiological versus standard multivitamin dose folic acid supplementation in renal transplant recipients. Arterioscler. Thromb. Vasc. Biol. (1999) 19(12):2918-2921.
49. ZANTVOORT FA, WALDMANN J, COLIC D, LISON AE: Incidence and treatment of hyperhomocysteinemia after renal transplantation. Tanspl. Proc. (2001) 33:3679-3680.
50. ARNESEN E, REFSUM H, BØNAA KH, UELAND PM, FØRDE OH, NORDREHAUG JE: Serum total homocysteine and coronary heart disease. Int. J. Epid. (1995) 24:704-709.
51. VERHOEF P, KOK FJ, KRUYSSEN DACM et al.: Plasma total homocysteine, B vitamins, and risk of coronary atherosclerosis. Arterioscler. Thromb. Vasc. Biol. (1997) 17:989-995.
52. STEHOUWER CDA, WEIJENBERG MP, VAN DEN BERG M, JAKOBS C, FESKENS EJM, KROMHOUT D: Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men. A 10-year follow-up. Arterioscler. Thromb. Vasc. Biol. (1998) 18:1895-1901.
53. BOTS ML, LAUNER LJ, LINDEMANS J et al.: Homocysteine and short-term risk of myocardial infarction and stroke in the elderly. Arch. Intern. Med. (1999) 159:38-44.
54. NYGÅRD O, NORDREHAUG JE, REFSUM H et al.: Plasma homocysteine levels and mortality in patients with coronary artery disease. N. Engl. J. Med. (1997) 337:230-236.
55. OMLAND T, SAMUELSSON A, HARTFORD M et al.: Serum homocysteine concentration as an indicator of survival in patients with acute coronary syndromes. Arch. Intern. Med. (2000) 160:1834-1840.
56. VERHOEF P, HENNEKENS CH, ALLEN RH, STABLER SP, WILLETT WC, STAMPFER MJ: Plasma total homocysteine and risk of angina pectoris with subsequent coronary artery bypass surgery. Am. J. Card. (1997) 79:799-801.
57. PERRY IJ, REFSUM H, MORRIS RW, EBRAHIM SB, UELAND PM, SHAPER AG: Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet (1995) 346:1395-1398.
58. VERHOEF P, HENNEKENS CH, MALINOW MR, KOK FJ, WILLETT WC, STAMPFER MJ: A prospective study of plasma homocysteine and risk of ischemic stroke. Stroke (1994) 25:1924-1930.
59. PETRI M, ROUBENOFF R, DALLAL GE, NADEAU MR, SELHUB J, ROSENBERG IH: Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet (1996) 348(9035):1120-1124.
60. MALINOW MR, KANG SS, TAYLOR LM et al.: Prevalence of hyperhomocysteinemia in patients with peripheral arterial occlusive disease. Circulation (1989) 79:1180-1188.
61. ARONOW WS, AHN C, SCHOENFELD MR: Association between plasma homocysteine and extracranial carotid arterial disease in older persons. Am. J. Cardiol. (1997) 79:1432-1433.
62. FERMO I, D'ANGELO SV, PARONI R, MAZZOLA G, CALORI G, D'ANGELO A: Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. Ann. Intern. Med. (1995) 123:747-753.
63. MALINOW MR, NIETO FJ, SZKLO M, CHAMBLESS LE, BOND G: Carotid artery intimal-medial wall thickening and plasma homocysteine in asymptomatic adults. Circulation (1993) 87:1107-1113.
64. KONECKY N, MALINOW MR, TUNICK PA et al.: Correlation between plasma homocysteine and aortic sclerosis. Am. Heart J. (1997) 133:534-540.
65. FONSECA V, GUBA SC, FINK LM: Hyperhomocysteinemia and the endocrine system: implications for atherosclerosis and thrombosis. Endoc. Reviews (1999) 20(5):738-759.
66. TAWAKOL A, OMLAND T, GERHARD M, WU JT, CREAGER MA: Hyperhomocysteinemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation (1997) 95:1119-1121.
67. NAPPO F, DE ROSA N, MARFELLA R et al.: Impairment of endothelial functions by acute hyperhomocysteinemia. and reversal by antioxidant vitamins. JAMA (1999) 281:2113-2118.
68. SHARMA N, ANDREWS TC: Endothelial function as a therapeutic target in coronary artery disease. Curr. Atheroscler. Reports (2000) 2(4):303-307.
69. 6 and risk of myocardial infarction in US physicians. J. Am. Col. Nutr. (1996) 15(2):136-143.
70. 6 from diet and supplements in relation to the risk of coronary heart disease among women. JAMA (1998) 279:359-364.
71. WOO KS, CHOOK P, LOLIN YI et al.: Folic acid improves arterial endothelial function in adults with hyperhomocystinemia. J. Am. Coll. Cardiol. (1999) 34:2002-2006.
72. 12)administration on endothelial dysfunction induced by post-methionine load hyperhomocysteinemia. Am. J. Cardiol. (1999) 84:1359-1361.
73. 6 improves biological markers of endothelial dysfunction. Br. J. Haematol. (1999) 107:776-778.
74. VAN DEN BERG M, BOERS GHJ, FRANKEN DG et al.: Hyperhomocysteinemia and endothelial cell dysfunction in young patients with peripheral arterial occlusive disease. Eur. J. Clin. Invest. (1995) 25:176-181.
75. 6 attenuates thrombin generation. Thomb. Res. (1999) 95(6 ):281-288.
76. DE VECCHI AF, PATROSSO C, NOVEMBRINO C et al.: Folate supplementation in peritoneal dialysis patients with normal erythrocyte folate: effect on plasma homocysteine. Nephron (2001) 89(3):297-302.
77. ISHIKAWA M, NAMIKI A, KUBOTA T et al.: Effect of hyperhomocysteinemia on endothelial activation and dysfunction in patients with end-stage renal disease. Am. J. Cardiol. (2001) 88(10):1203-1205.
78. 6 on progression of subclinical atherosclerosis: a randomized, placebo-controlled trial. Lancet (2000) 355(9203):517-522.
79. MORITA H, KURIHARA H, KUWAKI T et al.: Homocysteine as a risk factor for restenosis after coronary angioplasty. Thromb. Haemost. (2000) 84(1):27-31.
80. KUMBASAR SD, DINCER I, ERTAS F et al.: Hyperhomocysteinemia and restenosis. J. Cardiovasc. Risk (2001) 8(1):9-13.
81. SCHNYDER G, ROFFI M, FLAMMER Y, PIN R, HESS OM: Association of plasma homocysteine with restenosis after percutaneous coronary angioplasty. Eur. Heart J. (2002) 23(9):726-733.
82. MINER SE, HEGELE RA, SPARKES J et al.: Homocysteine, lipoprotein (a), and restenosis after percutaneous transluminal coronary angioplasty: a prospective study. Am. Heart J. (2000) 140(2):272-278.
83. 12, and folate to coronary in-stent restenosis. Am. J. Card. (2002) 89(5):295-299.
84. SCHNYDER G, MARCO R, PIN R et al.: Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N. Engl. J. Med. (2001) 345(22):1593-1600.
85. 6 on clinical outcome after percutaneous coronary intervention. The Swiss Heart Study: a randomized controlled trial. JAMA (2002) 288:973-979.
86. ZHENG H, DIMAYUGA C, HUDAIHED A, KATZ SD: Effect of dexrazoxane on homocysteine-induced endothelial dysfunction in normal subjects. Arterioscler. Thromb. Vasc. Biol. (2002) 22:e15-e18.